Stelara Aids in PsA Regardless of Previous Tx (CME/CE)
(MedPage Today) -- Patients who had used anti-TNFs still benefited from ustekinumab (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - August 11, 2016 Category: Rheumatology Source Type: news
Boehringer Ingelheim ’s investigational biologic cleared skin better, faster and for longer than ustekinumab in phase II psoriasis study
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Boehringer Ingelheim ’s investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Ustekinumab misses primary endpoint in atopic dermatitis
SCOTTSDALE, ARIZ. – Treatment with ustekinumab did not result in significant improvements in atopic dermatitis after 16 weeks, compared with placebo in a phase II study of adults with moderate to severe atopic dermatitis, Dr. Patrick Brunner reported at the annual meeting of the Society for... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 30, 2016 Category: Dermatology Source Type: news
Giant Cell Arteritis: Ustekinumab Shows Activity in Early TrialGiant Cell Arteritis: Ustekinumab Shows Activity in Early Trial
Ustekinumab was associated with lower steroid doses in some patients with GCA and reduced arterial wall thickening. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 12, 2016 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Ustekinumab Improves Spondylitis in Psoriatic ArthritisUstekinumab Improves Spondylitis in Psoriatic Arthritis
The anti-interleukin (IL)-12/IL-23 monoclonal antibody ustekinumab improves signs and symptoms of spondylitis in patients with psoriatic arthritis, according to a post-hoc analysis of data from the PSUMMIT-1 and PSUMMIT-2 trials. Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - May 3, 2016 Category: Orthopaedics Tags: Rheumatology News Source Type: news
J&J psoriasis drug Stelara eases Crohn's disease in second trial
(Reuters) - Johnson & Johnson's Stelara psoriasis drug has shown effectiveness against Crohn's disease in a second late-stage trial, the company said on Friday, bolstering prospects of its approval for the additional use. (Source: Reuters: Health)
Source: Reuters: Health - March 18, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
STELARA(R) Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy
Efficacy and Safety Results from Second STELARA® Phase 3 Induction Study (UNITI-1), the Largest Conducted to Date in Patients Refractory to TNF Inhibitors, Presented at the 11th Congress of ECCO
AMSTERDAM, March 18, 2016 -- (Healthcare Sales & Marke... Biopharmaceuticals, GastroenterologyJanssen, STELARA, ustekinumab, Crohn's disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 18, 2016 Category: Pharmaceuticals Source Type: news
Novartis’ Cosentyx® superior to Stelara in delivering lasting skin clearance for psoriasis patients
Cosentyx launched as first-line systemic indication for psoriasis in UK in 2015 and recently approved for psoriatic arthritis and ankylosing spondylitis in Europe (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 9, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Dermatology Patient care Research ankylosing spondylitis Cosentyx Latest News PASI psoriatic arthritis Source Type: news
Targeted Treatment May Reverse Alopecia AreataTargeted Treatment May Reverse Alopecia Areata
The psoriasis drug ustekinumab can spur hair regrowth and normalize immune function in patients with alopecia areata, according to the results of a study in three patients. Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 14, 2015 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news
Janssen seeks approval for Stelara in US and Europe to treat Crohn's disease
Janssen Biotech and Janssen-Cilag International (Janssen) have submitted two applications in the US and Europe for approval of Stelara (ustekinumab) to treat adults with moderately to severely active Crohn's disease. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - December 1, 2015 Category: Pharmaceuticals Source Type: news
Landmark clinical trial of a novel combination treatment for type 1 diabetes
(McGill University) Investigators at Montreal's Lady Davis Institute at the Jewish General Hospital and McGill University Health Centre have announced the start of a landmark clinical study aimed at restoring normal insulin secretion in people with longstanding type 1 diabetes. The treatment combines INGAP Peptide (ExsulinTM), which stimulates growth of the insulin secreting islets, and ustekinumab (SteleraTM), a drug approved for the treatment of psoriasis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 25, 2015 Category: Global & Universal Source Type: news
EADV: Investigational biologic rocks psoriasis world
COPENHAGEN – An investigational biologic agent that selectively inhibits the p19 subunit of interleukin-23 was the talk of the 2015 EADV congress based upon its striking outperformance of ustekinumab in a head-to-head phase II study in psoriasis patients.
Not only did the investigational agent,... (Source: Skin and Allergy News)
Source: Skin and Allergy News - October 25, 2015 Category: Dermatology Source Type: news
Stelara: A Coming Option for Crohn's? (CME/CE)
(MedPage Today) -- More than half of patients had clinical responses by week six of treatment (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 21, 2015 Category: Gastroenterology Source Type: news
J&J's Stelara Succeeds in Phase III Crohn's Disease TrialJ&J's Stelara Succeeds in Phase III Crohn's Disease Trial
Johnson & Johnson's Stelara (ustekinumab) was significantly better than placebo at inducing clinical response and remissions in patients with moderate to severe Crohn's disease, according to data from a late stage trial, providing ammunition for a potential expanded approval of the medicine. Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 20, 2015 Category: Allergy & Immunology Tags: Gastroenterology News Source Type: news
